AAVP is sufficiently financed to file an IND, with capital sourced from both institution and high-net worth family offices with particular focus in the biotechnology space. The Company will begin an active fund raise in the Spring of 2017 to raise sufficient funds to enroll its planned first in human Phase I clinical trial.